BioPharmSignal logoBioPharmSignal

Biotech News

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MeiraGTx (MGTX)MeiraGTxConference / presentation

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced

Related news

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

VYGRVoyager Therapeutics2026-06-29 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

OKYOOKYO Pharma2026-07-27 11:00 EST

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

OKYOOKYO Pharma2026-07-21 13:00 EST

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

View all latest news

MeiraGTx

Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...

Recent company news

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Stock data

Close
14.34 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States